Merck & Co Inc
MRK
Market Cap$319.49B
Close$
Earnings Call Q4 2023
February 1, 2024 - AI Summary
Merck reported strong revenue growth of 12% in 2023, driven by robust performance in oncology, vaccines, and animal health.
The company expects continued strong growth in 2024, with projected revenue between $62.7 billion and $64.2 billion, representing a growth rate of 4% to 7%.
Key products like KEYTRUDA and GARDASIL contributed to the revenue growth, with KEYTRUDA sales increasing by 22% to $6.6 billion.
Exclusive for Stockcircle Pro members
Sign up
$121.91
2.8% downside
Current Fair Value
2.8% downsideOvervalued by 2.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $319.49 Billion |
|---|---|
| Enterprise Value | $347.46 Billion |
| Dividend Yield | $2.9706 (2.35%) |
| Earnings per Share | $0.14 |
| Beta | 0.32 |
| Outstanding Shares | 2,532,643,872 |
| Avg 30 Day Volume | 10,095,275 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 875.32 |
|---|---|
| PEG | -622.4 |
| Price to Sales | 5.45 |
| Price to Book Ratio | 8.96 |
| Enterprise Value to Revenue | 5.78 |
| Enterprise Value to EBIT | 117.62 |
| Enterprise Value to Net Income | 951 |
| Total Debt to Enterprise | 0.1 |
| Debt to Equity | 0.93 |
Revenue Sources
No data
ESG Score
No data
About Merck & Co Inc
CEO: Kenneth Frazier